Johnson & Johnson Wins EU Approval for Teclistamab-Daratumumab Combo

Johnson & Johnson's bispecific antibody teclistamab (TECVAYLI®) has secured a European Commission indication extension for combination use with daratumumab in relapsed or refractory multiple myeloma (RRMM), a regulatory outcome that will prompt manufacturing and supply-chain reassessment for any site currently producing or distributing either biologic in the EU.

The approval, granted 24 August 2026, covers adults with RRMM who have received at least one prior line of therapy, shifting the combination into the second-line setting. The regulatory basis is Phase 3 MajesTEC-3 (NCT05083169) data, which demonstrated statistically significant improvements in both progression-free survival and overall survival versus standard-of-care regimens. Notably, more than 90% of patients who were progression-free at six months remained so at three years, a durability endpoint that will carry weight in European health technology assessment submissions.

From a manufacturing standpoint, the indication extension creates immediate demand-planning obligations. Teclistamab is a BCMAxCD3 bispecific antibody requiring cold-chain integrity across the distribution network; daratumumab is a well-established anti-CD38 monoclonal with its own fill-finish and storage requirements. Combining two biologics under a single treatment regimen means QA and supply-chain teams must coordinate lot-release schedules, shelf-life alignment, and concurrent GMP compliance documentation across potentially separate manufacturing sites and contract organisations.

The complementary mechanism underpinning the combination adds a layer of process complexity: daratumumab modulates the immune environment to enhance T-cell fitness and activation, amplifying the tumour-cell killing driven by teclistamab. Regulators evaluating the combination will have scrutinised comparability data and any process changes introduced during scale-up for the Phase 3 supply. Sites preparing for commercial-scale production of either agent should review their 21 CFR Part 211 and ICH Q10 quality management frameworks to ensure change-control documentation reflects any modifications made between clinical and commercial manufacturing.

For regulatory affairs leads operating in the EU, the extension also signals continued European Medicines Agency receptivity to bispecific antibody combinations supported by robust Phase 3 survival data, a precedent relevant to pipeline programmes in similar haematological indications. Country-level reimbursement negotiations will now determine the speed at which the combination reaches patients across member states, with pricing and access timelines varying considerably within the EU framework.

The durability of the MajesTEC-3 progression-free survival curve at three years will serve as the primary clinical benchmark as national health authorities evaluate cost-effectiveness submissions across EU member states.

Source: Johnson & Johnson via GlobeNewswire, 24 August 2026.